Terminated PHASE3 INTERVENTIONAL 5-arm NCT01436032

Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery

A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of Intravenous N1539 in Subjects After Abdominal Laparoscopic Surgery

Sponsor: Alkermes, Inc.

Conditions Laparoscopic Surgery

Interventions Ketorolac Tromethamine N1539 Placebo

Updated 7 times since 2017 Last updated: Mar 12, 2012 Started: Oct 31, 2011 Primary completion: Mar 31, 2012 Completion: Mar 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Alkermes, Inc.

More terminations from Alkermes, Inc.

A PHASE3 clinical study on Laparoscopic Surgery, this trial is terminated or withdrawn. The trial is conducted by Alkermes, Inc. and has accumulated 7 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Apr 2022 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alkermes, Inc.

Data source: Alkermes, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pasadena, United States